Computed tomography radiomics showed exploratory recurrence signals in mandibular osteoradionecrosis
In 24 surgically confirmed cases, three radiomic features differed nominally between pure osteoradionecrosis and osteoradionecrosis with recurrence.
In 24 surgically confirmed cases, three radiomic features differed nominally between pure osteoradionecrosis and osteoradionecrosis with recurrence.
After 66% of couch-angle changes, motion exceeded tolerance, and 0.5-millimetre and 0.5-degree errors reduced near-minimum target dose by 7.6%.
Combined high lactate dehydrogenase-5 expression and low tumor-infiltrating lymphocyte density independently identified higher biochemical relapse risk after prostate radiotherapy.
Adding pan-mucosal irradiation did not improve survival or reduce mucosal recurrence compared with nodal-only irradiation in thoroughly staged head and neck unknown primary cancer.
Across 500 clinical cases, automated planning preserved target coverage and was associated with lower doses to multiple critical structures than earlier manual planning.
After 13 years, first-line temozolomide and radiotherapy produced similar progression-free and overall survival across molecularly classified low-grade gliomas.
Across 1,760 patients, most grade 3 adverse events remained below 1.5%, although post-prostatectomy urinary incontinence reached 10.2% by eight years.
Three of four patients completed final imaging and lung stereotactic ablative radiotherapy within one assisted breath-hold, with only grade 1 adverse events.
Median survival was 8.3 months after proton reirradiation, with 5.6% grade 3–4 radiation necrosis and no survival difference versus photons.
Mean breast target displacement was below 1.3 mm in every direction, with calculated respiratory margins of approximately 1 mm.
A maximum left anterior descending coronary artery dose of at least 12 Gy was independently associated with higher long-term cardiac risk.
Gastrointestinal motility reduced single-fraction target coverage and broadened organ-at-risk dose ranges, while conventional fractionation substantially attenuated the interplay effect.
Four-year overall survival was 81.2%, and starting proton therapy at week 14 or later was not independently associated with worse outcomes.
The patient-specific framework outperformed three comparison methods and reconstructed respiratory anatomy in 15.6 milliseconds per frame.
Live magnetic resonance imaging–ultrasound fusion achieved under 4 mm registration accuracy and under 5 mm needle localization in two clinical implants.